Deregulation of the PP2A inhibitor SET shows promising therapeutic implications and determines poor clinical outcome in patients with metastatic colorectal cancer

Clinical Cancer Research

Volumn 21, Issue 2, 2015, Pages 347-356

  Cristóbal, Ion ^a   Rincón, Raúl ^a   Manso, Rebeca ^b   Caramés, Cristina ^a   Zazo, Sandra ^b   Madoz Gúrpide, Juan ^b   Rojo, Federico ^b   García Foncillas, Jesús ^a  

^a Instituto de Investigación Sanitaria Fundación Jiménez Díaz   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; FINGOLIMOD; FLUOROURACIL; OXALIPLATIN; PHOSPHOPROTEIN PHOSPHATASE 2A; PHOSPHOPROTEIN PHOSPHATASE INHIBITOR; PROTEIN SET; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CHAPERONE; PHOSPHOPROTEIN PHOSPHATASE 2; PLATINUM COMPLEX; SET PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL GROWTH; CELL PROLIFERATION; COLONOSPHERE FORMATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; ONCOGENE; ONCOGENE K RAS; ONCOGENE SET; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN DEREGULATION; PROTEIN FUNCTION; PROTEIN MODIFICATION; RETROSPECTIVE STUDY; SURVIVAL TIME; WESTERN BLOTTING; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENE EXPRESSION; IC50; KAPLAN MEIER METHOD; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; SECONDARY; TREATMENT OUTCOME; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION; HISTONE CHAPERONES; HUMANS; INHIBITORY CONCENTRATION 50; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTEIN PHOSPHATASE 2; RETROSPECTIVE STUDIES; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 84921059747     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-0724     Document Type: Article

References (38)

1. El Zouhairi M, Charabaty A, Pishvaian MJ.Molecularly targeted therapy for metastatic colon cancer: proven treatments and promising new agents. Gastrointest Cancer Res 2011;4:15-21.
2. Lermos C, Sack U, Schmid F, Juneja M, Stein U. Anti-metastatic treatment in colorectal cancer: targeting signaling pathways. Curr Pharm Des 2013;19:841-63.
3. Li M, Makkinje A, Damuni Z. The myeloid leukemia-associated protein SET is a potent inhibitor of protein phosphatase 2A. J Biol Chem 1996;271: 11059-62.
4. Seo SB, McNamara P, Heo S, Turner A, LaneWS, Chakravarti D. Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein. Cell 2001;104:119-30.
5. Kandilci A, Mientjes E, Grosveld G. Effects of SET and SET-CAN on the differentiation of the human promonocytic cell line U937. Leukemia 2004;18:337-40.
6. ten Klooster JP, Leeuwen I, Scheres N, Anthony EC, Hordijk PL. Rac1- induced cell migration requires membrane recruitment of the nuclear oncogene SET. Embo J 2007;26:336-45.
7. Canela N, Rodriguez-Vilarrupla A, Estanyol JM, Diaz C, Pujol MJ, Agell N, et al. The SET protein regulates G2/M transition by modulating cyclin B-cyclin-dependent kinase 1 activity. J Biol Chem 2003;278: 1158-64.
8. Trotta R, Ciarlariello D, Dal Col J, Allard J II, Neviani P, Santhanam R, et al. The PP2A inhibitor SET regulates natural killer cell IFN-gamma production. J Exp Med 2007;204:2397-2405.
9. Trotta R, Ciarlariello D, Dal Col J, Mao H, Chen L, Briercheck E, et al. The PP2A inhibitor SET regulates granzyme B expression in human natural killer cells. Blood 2011;117:2378-84.
10. Cervoni N, Detich N, Seo SB, Chakravarti D, Szyf M. The oncoprotein Set/TAF-1beta, an inhibitor of histone acetyltransferase, inhibits active demethylation of DNA, integrating DNA methylation and transcriptional silencing. J Biol Chem 2002;277:25026-31.
11. Westermarck J, Hahn WC. Multiple pathways regulated by the tumor suppressor PP2A in transformation. Trends Mol Med 2008;14:152-60.
12. Al-Murrani SW, Woodgett JR, Damuni Z. Expression of I2PP2A, an inhibitor of protein phosphatase 2A, induces c-Jun and AP-1 activity. Biochem J 1999;341:293-8.
13. Fan Z, Beresford PJ, Oh DY, Zhang D, Lieberman J. Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor. Cell 2003;112:659-72.
14. Kim JY, Lee KS, Seol JE, Yu K, Chakravarti D, Seo SB. Inhibition of p53 acetylation by INHAT subunit SET/TAF-Ib represses p53 activity. Nucleic Acids Res 2012;40:75-87.
15. Liu GP, Wei W, Zhou X, Zhang Y, Shi HH, Yin J, et al. I(2)(PP2A) regulates p53 and Akt correlatively and leads the neurons to abort apoptosis. Neurobiol Aging 2012;33:254-64.
16. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Polizello AC, et al. Accumulation of the SET protein in HEK293T cells andmild oxidative stress: cell survival or death signaling. MolCell Biochem 2012;363:65-74.
17. Neviani P, Santhanam R, Trotta R, Notari M, Blaser BW, Liu S, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355-68.
18. Cristobal I, Garcia-Orti L, Cirauqui C, Cortes-Lavaud X, Garcia-Sanchez MA, Calasanz MJ, et al. Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia. Haematologica 2012;97: 543-50.
19. Sirma Ekmekci S, G Ekmekci C, Kandilci A, Gulec C, AkbiyikM, Emrence Z, et al. SET oncogene is upregulated in pediatric acute lymphoblastic leukemia. Tumori 2012;98:252-6.
20. Leopoldino AM, Squarize CH, Garcia CB, Almeida LO, Pestana CR, Sobral LM, et al. SET protein accumulates in HNSCC and contributes to cell survival: antioxidant defense, Akt phosphorylation and AVOs acidification. Oral Oncol 2012;48:1106-13.
21. Christensen DJ, Chen Y, Oddo J, Matta KM, Neil J, Davis ED, et al. SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target. Blood 2011;118:4150-8.
22. Switzer CH, Cheng RYS, Vitek TM, Christensen DJ, Wink DA, Vitek MP. Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy. Oncogene 2011;30:2504-13.
23. Mukhopadhyay A, Tabanor K, Chaguturu R, Aldrich JV. Targeting inhibitor 2 of protein phosphatase 2A as a therapeutic strategy for prostate cancer treatment. Cancer Biol Ther 2013;14:962-72.
24. Chao A, Tsai CL, Wei PC, Hsueh S, Chao AS, Wang CJ, et al. Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma. Cancer Lett 2010; 291:99-107.
25. Mumby M. PP2A: unveiling a reluctant tumor suppressor. Cell 2007;130: 21-4.
26. Janssens V, Goris J, Van Hoof C. PP2A: the expected tumor suppressor. Curr Opin Genet Dev 2005;15:34-41.
27. Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2Aregulatory subunits and cancer. Biochim Biophys Acta 2009;1795:1-15.
28. Cristobal I, Garcia-Orti L, Cirauqui C, Alonso MM, Calasanz MJ, Odero MD. PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia 2011;25:606-14.
29. Kalev P, Sablina AA. Protein phosphatase 2A as a potential target for anticancer therapy. Anticancer Agents Med Chem 2011;11:38-46.
30. Perrotti D, Neviani P. Protein phosphatise 2A: a target for anticancer therapy. Lancet Oncol 2013;14:e229-38.
31. Saddoughi SA, Gencer S, Peterson YK, Ward KE, Mukhopadhyay A, Oaks J, et al. Sphingosine analogue drug FTY720 targets I2PP2A/SET andmediates lung tumor suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med 2013;5:105-21.
32. Cristobal I, Manso R, Rincon R, Carames C, Senin C, Borrero A, et al. PP2A inhibition is a common event in colorectal cancer and its restoration using FTY720 shows promising therapeutic potential. Mol Cancer Ther 2014; 13:938-47.
33. Bitarte N, Bandres E, Boni V, Zarate R, Rodríguez J, Gonzalez-Huarriz M, et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells 2011;29: 1661-71.
34. Cristobal I, Rincon R, Manso R, Madoz-Gurpide J, Carames C, del Puerto-Nevado L, et al. Hyperphosphorylation of PP2A in colorectal cancer and the potential therapeutic value showed by its forskolininduced dephosphorylation and activation. Biochim Biophys Acta 2014;1842:1823-9.
35. Generali D, Buffa FM, Berruti A, Brizzi MP, Campo L, Bonardi S, et al. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and 470 resistance in patients with breast cancer. J Clin Oncol 2009;27:227-34.
36. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clarck GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005;23:9067-72.
37. Zhang L, Wang HD, Ji XJ, Cong ZX, Zhu JH, Zhou Y. FTY720 for cancer therapy (review). Oncol Rep 2013;30:2571-8.
38. Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, et al. Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models. Clin Cancer Res 2013;19:138-47.